PDCD1 and neoplasm: Interestingly, the combination of D16F7 mAb with an anti-CTLA-4 mAb (UC10-4F10-1 clone), or with an anti-PD-1 (RMP1-14 clone) (four doses of 10 mg/kg every two days) was more effective in suppressing tumor growth compared to each mAb administered as monotherapy [120].